The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
| العنوان: | The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis |
|---|---|
| المؤلفون: | Nian Wang, Lei Zhao, Yilin Yang, Peilin Pang, Zihong Xie, Hengrui Liang |
| المصدر: | Translational Cancer Research |
| بيانات النشر: | AME Publishing Company, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, safety, Cancer Research, medicine.medical_specialty, biology, business.industry, programmed cell death 1 protein (PD-1 protein), medicine.disease, Meta-analysis, non-small cell lung cancer (NSCLC), Internal medicine, PD-L1, biology.protein, Medicine, Radiology, Nuclear Medicine and imaging, Original Article, Non small cell, business, Lung cancer, programmed cell death 1 ligand 1 (PD-L1) |
| الوصف: | Background In both first or subsequent therapy of patients with non-small cell lung cancer (NSCLC), some programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have shown prominent efficacy and safety. However, the disease spectra of side effects in different therapy time might exist heterogeneity. In this meta-analysis, we assessed and compared the safety of PD-1/PD-L1 inhibitors in first or subsequent line therapy. And the system-specific disease spectra of both treatment-related adverse events (trAEs) and immune-related adverse events (irAEs) were summarized. Methods We performed a comprehensive search of online databases. Incidence and its 95% confidence interval (95% CI) were chosen as the main outcome to assess safety. The incidence of trAEs/irAEs was calculated, including discontinuation and death results. Besides, the most common trAEs/irAEs and system-specific treatment-related/immune-related disease spectra in different therapy lines were also collected. Results In total, 18 studies (5,649 patients) were included. First-line therapy had a higher risk of high-grade trAEs, any-grade irAEs and high-grade irAEs comparing with subsequent therapy (19.4% vs. 13.0%, P |
| اللغة: | English |
| تدمد: | 2219-6803 2218-676X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea210294cf00bfb78fe2e6d1e725c18f http://europepmc.org/articles/PMC8797275 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....ea210294cf00bfb78fe2e6d1e725c18f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22196803 2218676X |
|---|